Abstract Background
Renal involvement is uncommon in diffuse large B-cell lymphoma. Recent data suggest it is an independent risk factor for central nervous system relapse. We reviewed the clinical features, risk of central nervous system involvement, and survival for patients with involvement of the kidney at diagnosis.
Design and Methods
All patients with diffuse large B-cell lymphoma and renal involvement diagnosed from January 1, 1982 to December 31, 2008 at the British Columbia Cancer Agency were retrospectively identified in the Lymphoid Cancer Database. Patients were included if they were >16 years old, had advanced stage (stage III /IV, or stage I /II with B symptoms or bulky (>10cm)) disease and were treated with curative intent. Central nervous system involvement was diagnosed by cerebrospinal fluid cytology, radiology or clinically.
Results
We identified 55/2656 (2%) patients with diffuse large B-cell lymphoma and renal involvement at diagnosis with the following characteristics n(%): male:female 2:1; median age 58 years; bilateral renal involvement 24(44%); stage IV disease 50(91%); international prognostic index 3,4 or 5 52(95%); glomerular filtration rate < 30 mL/min 9(16%); elevated lactate dehydrogenase 46(84%). Twenty-five (46%) patients received CHOP plus rituximab and 30(54%) received CHOP-like regimens without rituximab. In total, 20(36%) patients had central nervous system involvement: 4 at the time of diagnosis and 16 at relapse. The median time to central nervous system relapse was 5.6 months (range 1.2 months-4.6 years), and was not impacted by the addition of rituximab (p=0.547). The 5 year overall and progression-free survivals for the whole cohort were 29% and 25%, respectively. In patients who received rituximab, there was a trend towards improved 5-year overall (43% versus 18%, p=0.071) and progression-free (40% versus 13%, p=0.057) survival.
Conclusion
There is an exceptionally high incidence of central nervous system relapse in patients with diffuse large B-cell lymphoma and kidney involvement at diagnosis. The addition of rituximab may improve overall survival in this poor risk population, likely through improved control of systemic disease.
Introduction
Renal parenchymal involvement is uncommon in diffuse large B-cell lymphoma (DLBCL). In almost all cases, renal involvement appears to be a secondary process: either by direct extension from a retroperitoneal mass or via hematogenous spread in the setting of disseminated disease.(1,2) Primary renal non-Hodgkin's lymphoma is even more uncommon, and only a few cases have been reported in the literature. (3) (4) (5) (6) (7) (8) There are limited data describing the clinical course and outcomes of patients with renal involvement and many prior studies were based on older lymphoma classification systems. (9) (10) (11) (12) Retrospective cohort studies reveal that these patients tend to present with widespread disease and have a poor outcome in part due to a high rate of CNS relapse. (13, 14) A recently published report from the British Columbia Cancer Agency (BCCA) showed that kidney involvement is an independent risk factor for central nervous system (CNS) relapse in patients with DLBCL in both the pre and post rituximab treatment eras. (14) However, to date, there are no published studies directly evaluating the risk of CNS relapse exclusively in patients with renal involvement, especially in those treated with rituximab.
The purpose of this study was two-fold: 1) To evaluate the incidence of CNS relapse in an expanded cohort of patients with DLBCL and kidney involvement and 2) To determine the impact of rituximab on outcome and CNS relapse in this patient population
Design and Methods

Patient selection
All patients with biopsy-proven DLBCL by the current WHO classification and extranodal renal involvement, diagnosed from 1 January 1982 to 31 Baseline clinical, laboratory, pathology, and imaging information for each patient were obtained from their paper and/or electronic medical records. Follow-up information, including details on relapse and death, was obtained primarily through the Cancer 6 Agency Information System. In those patients who relapsed, the sites of relapse were documented. When necessary, local physicians and hospitals were contacted to complete the follow-up data. This study was approved by the University of British Columbia BCCA Research Ethics Board.
Statistical analysis
The primary study endpoint was the time to CNS relapse (TTCNS), defined as new involvement of the CNS after chemotherapy, in isolation or as part of progressive disease involving other sites. CNS involvement was diagnosed by CSF cytology, brain imaging (CT or MRI), or objective neurological examination findings. TTCNS was calculated from the initial pathologic date of diagnosis to the date of CNS relapse. Patients with CNS involvement at diagnosis were not included in the TTCNS analyses. 
Results
Baseline Characteristics
A total of 2656 patients with DLBCL diagnosed between 1982 and 2008 were initially identified. Sixty-two had renal involvement at diagnosis. Seven were excluded: 2 Baseline characteristics are displayed in Table 1 . The median age at diagnosis was 58 years, and most patients were male (67%). The majority of patients had poor prognostic features, including elevated LDH (84%), stage IV (91%), performance status >2 (69%), high or high intermediate IPI score (>3) (67%), involvement of other extranodal sites (91%), and bulky disease (56%). Severe renal failure was present in 16% of patients, and 44% had bilateral renal involvement.
In total, 30(54%) patients were treated with CHOP-like chemotherapy and 25(46%) with R-CHOP (table 1). Intrathecal prophylaxis was given to 8 of 51 (15%) patients without known CNS involvement at diagnosis. Four patients had CNS disease at diagnosis: three were treated with CHOP (with IT chemotherapy plus whole brain irradiation in one patient, whole brain irradiation in another patient, corticosteroids in the third patient), and one was treated with R-CHOP plus IT chemotherapy.
CNS Involvement
Twenty (36%) patients had CNS involvement at some point in their disease course: Table   2 ). The majority of CNS events were diagnosed by CSF cytology (n=11) or CNS imaging (n=7). About half of CNS events were leptomeningeal (n=11) and the other half were parenchymal (n=8); only one patient had involvement of both compartments. Almost all patients received at least one form of treatment for CNS involvement: whole brain radiation and intrathecal chemotherapy were the most commonly used therapies. None of the patients received high dose chemotherapy and autologous stem cell transplantation.
Risk factors for CNS relapse
There were no significant differences in most baseline characteristics between those who had CNS involvement and those who did not, with the exception of a higher proportion of bulky disease in those without a CNS event (69% versus 35%, p=0.021) and conversely, there was a trend towards a higher risk CNS disease in patients with bone marrow (p=0.076) and testicular involvement (p=0.053) at diagnosis ( Table 1) .
Patients who suffered a CNS relapse were less likely to have achieved a complete remission (CR) to primary systemic therapy than those who did not (20% versus 54%, p=0.022). Similarly, those who suffered a CNS relapse were more likely to have stable or progressive disease to chemotherapy (40% versus 11%, p=0.020). However, among the 16 patients who achieved a CR, the addition of rituximab did not influence TTCNS (2- year TTCNS 21% CHOP versus 17% R-CHOP, p=0.692).
Patient outcomes
The 5-year OS and PFS for the whole cohort were 29% and 25%, respectively, reflecting an aggressive course. There was a trend towards an improved 5-year OS (43% versus 18%, p=0.071) and PFS (40% versus 13%, p=0.057) in patients treated with R-CHOP, despite their poor prognostic characteristics, as shown in Figures 1 and 2 . Patients with severe renal failure did not experience worse outcomes (OS p=0.220, PFS p=0.480).
Outcomes were equally poor regardless of whether patients had CNS involvement or systemic relapse, with median OS slightly less than one year. Following CNS relapse, all patients died of progressive disease, with a very short median survival of 2.2 months (range 2 weeks -2.6 years).
Discussion
In keeping with other studies using modern imaging techniques, we observed a low incidence of kidney involvement at the time of diagnosis in patients with DLBCL(2%). (9) (10) (11) (12) (13) (14) This may underestimate the true involvement however, as older autopsy series reveal that the incidence may be as high as 50% in patients who ultimately succumb to their disease.(9,20-23) Renal parenchymal involvement does not necessarily result in impaired organ function, suggesting that a number of patients may have microscopic, subclinical kidney involvement at diagnosis. (1, 6, 11) Consistent with prior reports, we observed that renal involvement occurred in the setting of extensive nodal(11) and extranodal(9) disease. Indeed, 90% of our patients had at least two extranodal sites involved at presentation. The presence of more than one extranodal site has been consistently identified as an independent risk factor for CNS relapse in several studies. (13, (24) (25) (26) (27) (28) . CNS relapse occurred early after completion of primary systemic therapy and CNS involvement was also found in four patients at the time of diagnosis. Since staging lumbar puncture and brain imaging were not routinely performed on all patients, it is possible that a proportion may have had occult CNS disease at diagnosis. Given the low sensitivity of CSF cytology, a negative CSF cytology is probably insufficient to rule out subclinical CNS involvement in such high-risk patients; in these cases, other techniques such as flow cytometry should be employed to increase detection rates. (29) (30) (31) The detection of subclinical CNS involvement may better guide treatment recommendations and prognosis for such patients.
Although the mechanism of lymphoma dissemination into the CNS remains unclear, the role of adhesion molecules, chemokines, and matrix metalloproteinases in tumor invasion and metastasis has become increasingly recognized. (32, 33) . The expression of certain genes (34, 35) and adhesion molecules on the surface of non-Hodgkin lymphoma cells (36, 37) has been associated with a tendency towards extranodal involvement, tumor aggressiveness, and worse outcomes. These observations provide a biologic hypothesis accounting for the high rates of CNS involvement seen at diagnosis and relapse in our patient cohort.
The poor outcomes reported in the current study are similar to prior reports of patients with non-Hodgkin lymphoma involving the kidneys treated with combination chemotherapy in the pre-rituximab era. Such studies show rapid improvement in renal function and tumor size, but treatment failure is common. (9, 11, 12) . The addition of rituximab appears to improve both progression-free and overall survival. However, it does not appear to reduce rates of CNS relapse, although this finding is limited by our small sample size. A recent post-hoc analysis of 1222 patients with aggressive B-cell non-Hodgkin's lymphoma treated in the RICOVER-60 study showed that those treated with R-CHOP have lower incidence of CNS relapse (2 year TTCNS relapse 4.1% versus 6.9%, RR 0.58, p=0.046) however, the absolute difference is marginal in this low risk population. (27) . Further, our previously published results of 435 patients suggest that rituximab may have a greater impact on reducing the risk of CNS relapse in patients who have achieved a CR, perhaps through better systemic disease control. (14) Given that most relapses in the current study occurred early, subclinical disease at diagnosis may have been underappreciated and rituximab may not be sufficient to eradicate CNS disease in this group due to poor penetration. Current strategies to prevent CNS relapse in patients with aggressive histology lymphoma in the rituximab era, including intrathecal chemotherapy, are generally ineffective. (14, 27, 28) A recent retrospective study of 65 selected patients with high-risk DLBCL receiving primary chemoimmunotherapy concurrently with intravenous highdose methotrexate and leucovorin rescue suggests that this strategy may be associated with a lower risk of CNS relapse,(38) but prospective evaluation is necessary.
In summary, patients with DLBCL and kidney involvement at diagnosis have a poor prognosis in part due to the high and early incidence of CNS relapse. The addition of rituximab appears to modestly improve overall survival in this poor risk population, likely due to enhanced systemic disease control as the risk of CNS relapse is unaltered.
Clinicians should consider evaluating these patients for CNS involvement at the time of diagnosis and staging, even in the absence of neurological signs and symptoms. R-CHOP is not enough therapy in patients with renal involvement with or without CNS disease, and therefore improved diagnostic and treatment modalities are necessary for this population. 0.209 *Excludes IT chemotherapy given to 2 of 4 patients with known CNS involvement at diagnosis. **Two patients died of acute treatment toxicity, and two patients have unobtainable treatment response information. 
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